Navigation Links
Scott & White Healthcare clinical trials target lymphoma, leukemia
Date:5/5/2010

Scott & White's Cancer Research Institute (CRI) is participating in an international study that targets adult relapsed or refractory B-cell Non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

"This study is important in our efforts to find new and better ways to treat patients with leukemia or lymphoma," said Arthur E. Frankel, M.D., director of Scott & White's Cancer Research Institute, and principal investigator for the Temple portion of the study. "Scott & White, as well as the entire Central Texas community, are fortunate to be included in this international research."

The Phase I/II study is open to eligible patients with previously treated B-cell non-Hodgkin's lymphoma (NHL), B-cell chronic lymphocytic leukemia (CLL), to include small lymphocytic lymphoma (SLL). B-cell lymphomas account for 80-90% of all Non-Hodgkin's Lymphomas. The clinical trial will evaluate the safety, tolerability, and efficacy of an investigative therapeutic research agent called CAT-8015.

This research will ultimately include 30 sites in the U.S., Canada and Europe and from 110 to 140 subjects. The study will last about 30 months.

"We want to determine if this agent is effective in destroying cancer cells using varying doses," said Dr. Frankel.

Descriptions:

  • Chronic lymphocytic leukemia (CLL), more common in people age 60 and older, is a B-cell disorder in which white blood cells live longer than normal and accumulate in the blood and bone marrow and sometimes the lymph nodes. This accumulation of white blood cells crowds out healthy lymphocytes and causes immune system problems. About 15,490 new cases of CLL were diagnosed in 2009.
  • CLL and Small Lymphocytic Lymphoma (SLL) are the same disease with slight variations. When the cancer cells are primarily in the lymph nodes, it's called SLL.
  • Follicular Lymphoma, a slow-growing Lymphoma, accounts for 20-30% of the cases of Non-Hodgkin's Lymphoma. It occurs equally among males and female adults over the age of 60.
  • Diffuse Large B-Cell Lymphoma is an aggressive Non-Hodgkin's Lymphoma (NHL) that occurs in B-cells, and accounts for two out of five cases of NHL.
  • Mantle cell lymphoma (MCL) accounts for about 1 in 20 Non-Hodgkin's Lymphoma diagnoses in the United States; and typically occurs in patients over 30 years old, most frequently in males over the age of 50.


'/>"/>

Contact: Katherine Voss
kvoss@swmail.sw.org
254-724-4097
Scott & White Healthcare
Source:Eurekalert

Related medicine news :

1. Scottsdale Veterinary Pharmacy Celebrates Success in Business By Dodging Veterinary Drug Shortages
2. New Varicose Vein Treatment Center Opens in Prescott, Arizona
3. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
4. Allergy Relief, Chiropractic and Biofeedback Provided at New Absolute Health Clinic in Scottsdale, Arizona
5. SUNZ Insurance Company Selects Scott Robertson as President
6. James Scott Farrin Supports Radiothon for Duke Children's Hospital
7. Scott & White Healthcare pathologist is co-investigator on breast cancer study
8. Scott & White Memorial Hospital uses device to revolutionize treatment of traumatic aortic injury
9. Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period
10. Scott Roeder Trial: Randall Terry, Operation Rescue Founder and Insurrecta Nex Members to Attend Trial in Wichita
11. New study shows TGen spin-off boosts Scottsdale economy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Thank you ... Diego on February 8-10. , This event was exclusive to providers and offered ... , The meeting took place at the Manchester Grand Hyatt where attendees gathered for ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Bacteria and fungi are probably not the first ... bad. In fact, including the right microorganisms in your diet can actually improve health outcomes. ... , This is the topic of a new peer-reviewed paper led by ...
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. ... smile makeovers without requiring a referral. Trimble Dental offers a variety of ... dentistry and dental implants. Whether patients have discolored, crooked or missing teeth in ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... site attention and engagement over the household brands of Top-20 pharma by optimizing ... discuss how partnering with the right outsourcing payments provider can provide the technology, ...
(Date:3/27/2017)... Reston, VA (PRWEB) , ... March 27, 2017 ... ... mobile application containerization, today announced it will co-exhibit with technology partners LG Business ... held at the Marriott Metro Center in Washington D.C., will provide education and ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immunotherapy successfully passed early toxicology and efficacy studies. The ... to target a specific protein, MAGE A, in an ... breast cancer. After 4 weeks of ... to show very little toxicity in a full toxicology ...
(Date:3/27/2017)... 27, 2017  Sanderling Ventures, portfolio company, Torax ... division of Johnson & Johnson. Torax manufactures and markets ... of gastro-esophageal reflux disease (GERD). The LINK device ... and the procedure is currently available in the ... Medical was founded by Sanderling Ventures, Mayo Medical ...
(Date:3/27/2017)... AVIV, Israel , March 27, 2017 ... on oncology and immunology, announced today that AGI-134, an immunotherapy ... announced acquisition of Agalimmune Ltd., will be featured at the ... in Washington, DC to be ... ...
Breaking Medicine Technology: